A Murias

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

Miguel Martín, Álvaro Rodríguez-Lescure, Emilio Alba et al. · Breast Cancer Research and Treatment · 2009 · 82 citations

Medicine, Oncology, Pharmacology +13

Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer

N. Batista, G. Pérez-Manga, Manuel Constenla et al. · British Journal of Cancer · 2004 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

Concepción de la Piedra, Antonio Alcaraz, Joaquim Bellmunt et al. · British Journal of Cancer · 2013 · 34 citations · Full text

Medicine, Oncology, Pharmacology +17

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study

Antonio Alcaraz, Raquel González-López, Juan Moróte et al. · British Journal of Cancer · 2013 · 22 citations · Full text

Medicine, Oncology, Pharmacology +17